Pimavanserin
ACP-103-055
Phase 3 small_molecule terminated
Quick answer
Pimavanserin for Adjunctive Treatment of Major Depressive Disorder is a Phase 3 program (small_molecule) at Acadia Pharmaceuticals B.V. with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Acadia Pharmaceuticals B.V.
- Indication
- Adjunctive Treatment of Major Depressive Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated